Affordable Access

Pharmacogenomics Related to Growth Disorders.

Authors
Journal
Hormone Research in Paediatrics
1663-2818
Publisher
S. Karger AG
Publication Date
Disciplines
  • Biology
  • Medicine
  • Pharmacology

Abstract

Growth disorders resulting in short stature are caused by a wide range of underlying pathophysiological processes. To improve height many of these conditions are treated with recombinant human growth hormone (rhGH). However, substantial inter-individual variability in growth response both in the short and long-term is recognised. Over the last decade, disease-specific growth prediction models have been developed that the clinician can use to define a child's potential response to rhGH and to optimise starting and maintenance doses of rhGH. These models, however, are not able to predict all the variations in treatment response. There has, therefore, been recent interest in using genetic information to contribute to the evaluation of responses to rhGH, including high-throughput technologies for assessing DNA markers (genome) and mRNA transcripts (transcriptome) as pharmacogenomic tools. This review will focus on how these pharmacogenomic approaches are being applied to growth disorders. © 2013 S. Karger AG, Basel.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Pharmacogenomics related to growth disorders.

on Hormone research in pædiatrics 2013

Genomics and pharmacogenomics of brain disorders.

on Current Pharmaceutical Biotech... April 2012

Isolated human growth hormone deficiency and relat...

on Israel journal of medical scie... 1973

Noonan syndrome and related disorders: Alterations...

on Reviews in Endocrine and Metab... Dec 01, 2006
More articles like this..